|Bid||77.93 x 1000|
|Ask||77.96 x 800|
|Day's range||76.80 - 78.92|
|52-week range||69.10 - 95.19|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||36.56|
|Earnings date||28 Apr 2021 - 03 May 2021|
|Forward dividend & yield||0.98 (1.25%)|
|Ex-dividend date||25 Feb 2021|
|1y target est||92.18|
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Baxter...
The main point of investing for the long term is to make money. But more than that, you probably want to see it rise...
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced it has appointed David S. Wilkes, M.D., dean, University of Virginia School of Medicine, and co-founder and chief scientific officer of biotech start-up ImmuneWorks Inc., to its board of directors. Dr. Wilkes will serve on Baxter’s Quality, Compliance and Technology Committee. Additionally, Baxter has appointed Albert P.L. Stroucken, former executive chairman and chief executive officer, Owens-Illinois, Inc., and a Baxter director since 2004, as its lead independent director. Mr. Stroucken, who previously served as the chairman of the Audit Committee, will succeed Thomas T. Stallkamp, who has served as lead independent director from May 2014 to February 2021. Mr. Stallkamp will continue to serve as a director of the board. Both new appointments are effective today and will bring the total number of directors serving the company to 13.